DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3206-666-674$20.00
DMD 32:666-674, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vaclavikova, R.
Right arrow Articles by Gut, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vaclavikova, R.
Right arrow Articles by Gut, I.

DIFFERENT IN VITRO METABOLISM OF PACLITAXEL AND DOCETAXEL IN HUMANS, RATS, PIGS, AND MINIPIGS

Radka Vaclavikova, Pavel Soucek, Lenka Svobodova, Pavel Anzenbacher, Petr Simek, F. Peter Guengerich, and Ivan Gut

National Institute of Public Health, Prague, Czech Republic (R.V., P.S., L.S., I.G.); Medical Faculty, Palacky University, Olomouc, Czech Republic (P.A.); Entomologic Institute of the Academy of Sciences of the Czech Republic, Ceske Budejovice, Czech Republic (P.S.); and Department of Biochemistry and Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee (F.P.G.)

We investigated cytochrome P450 (P450)-catalyzed metabolism of the important cancer drugs paclitaxel and docetaxel in rat, pig, minipig, and human liver microsomes and cDNA-expressed P450 enzymes. In rat microsomes, paclitaxel was metabolized mainly to C3'-hydroxypaclitaxel (C3'-OHP) and to a lesser extent to C2-hydroxypaclitaxel (C2-OHP), di-hydroxypaclitaxel (di-OHP), and another unknown monohydroxylated paclitaxel. In pig and minipig microsomes, this unknown hydroxypaclitaxel was the main metabolite, whereas C3'-OHP was a minor product. In minipigs, C2-OHP was the next minor product. In human liver microsomes, 6{alpha}-hydroxypaclitaxel (6{alpha}-OHP) was the main metabolite, followed by C3'-OHP and C2-OHP. Among different cDNA-expressed human P450 enzymes (CYP1A2, 1B1, 2A6, 2C9, 2E1, and 3A4), only CYP3A4 enzyme formed C3'-OHP and C2-OHP. Docetaxel was metabolized in pig, minipig, rat, and human liver microsomes mainly to hydroxydocetaxel (OHDTX), whereas CYP3A-induced rat microsomes produced primarily diastereomeric hydroxyoxazolidinones. Human liver microsomes from 10 different individuals formed OHDTX at different rates correlated with CYP3A4 content. Troleandomycin as a selective inhibitor of CYP3A inhibited the formation of C3'-OHP, C2-OHP, and di-OHP, as well as the unknown OHP produced in rat, minipig, and pig microsomes. In human liver microsomes, troleandomycin inhibited C3'-OHP and C2-OHP formation, and a suitable inhibitor of human CYP2C8, fisetin, strongly inhibited the formation of 6{alpha}-OHP, known to be catalyzed by human CYP2C8. In conclusion, the metabolism of docetaxel is the same in all four species, but metabolism of paclitaxel is different, and 6{alpha}-OHP remains a uniquely human metabolite. Pigs and minipigs compared with each other formed the same metabolites of paclitaxel.


Address correspondence to: Radka Vaclavikova, National Institute of Public Health, Srobárova 48, 100 42 Prague 10, Czech Republic. E-mail: rvaclavikova{at}szu.cz




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
J.-W. Zhang, G.-B. Ge, Y. Liu, L.-M. Wang, X.-B. Liu, Y.-Y. Zhang, W. Li, Y.-Q. He, Z.-T. Wang, J. Sun, et al.
Taxane's Substituents at C3' Affect Its Regioselective Metabolism: Different in Vitro Metabolism of Cephalomannine and Paclitaxel
Drug Metab. Dispos., February 1, 2008; 36(2): 418 - 426.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. Vuppugalla, S.-Y. Chang, H. Zhang, P. H. Marathe, and D. A. Rodrigues
Effect of Commonly Used Organic Solvents on the Kinetics of Cytochrome P450 2B6- and 2C8-Dependent Activity in Human Liver Microsomes
Drug Metab. Dispos., November 1, 2007; 35(11): 1990 - 1995.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. L. Bradshaw-Pierce, S. G. Eckhardt, and D. L. Gustafson
A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man
Clin. Cancer Res., May 1, 2007; 13(9): 2768 - 2776.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Henningsson, S. Marsh, W. J. Loos, M. O. Karlsson, A. Garsa, K. Mross, S. Mielke, L. Vigano, A. Locatelli, J. Verweij, et al.
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel
Clin. Cancer Res., November 15, 2005; 11(22): 8097 - 8104.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. J. Komoroski, R. A. Parise, M. J. Egorin, S. C. Strom, and R. Venkataramanan
Effect of the St. John's Wort Constituent Hyperforin on Docetaxel Metabolism by Human Hepatocyte Cultures
Clin. Cancer Res., October 1, 2005; 11(19): 6972 - 6979.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. Baranova, E. Anzenbacherova, P. Anzenbacher, and P. Soucek
MINIPIG CYTOCHROME P450 2E1: COMPARISON WITH HUMAN ENZYME
Drug Metab. Dispos., June 1, 2005; 33(6): 862 - 865.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. Katoh, T. Matsui, M. Nakajima, C. Tateno, M. Kataoka, Y. Soeno, T. Horie, K. Iwasaki, K. Yoshizato, and T. Yokoi
EXPRESSION OF HUMAN CYTOCHROMES P450 IN CHIMERIC MICE WITH HUMANIZED LIVER
Drug Metab. Dispos., December 1, 2004; 32(12): 1402 - 1410.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.